logo
  

Plum Creek Timber Profit Rises, Cuts FY14 Outlook

Plum Creek Timber Co., Inc. (PCL) Monday reported an increase in profit for the second-quarter as revenues grew, with both earnings and revenues beating Wall Street estimates. Moving ahead, the company lowered its earnings outlook for the full year.

"Our second quarter results were much as we anticipated despite lower-than-planned harvest volumes in the South," said CEO Rick Holley.

Seattle, Washington-based Plum Creek's second-quarter profit rose to $55 million or $0.31 per share from $46 million or $0.28 per share last year. On average, ten analysts polled by Thomson Reuters expected earnings of $0.30 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the second quarter grew to $356 million from $303 million last year. Nine analysts had a consensus revenue estimate of $353.73 million for the quarter.

Looking ahead to the third quarter, the company expects earnings of $0.27 to $0.32 per share. Analysts currently expect earnings of $0.46 per share for the quarter.

The company lowered its earnings outlook for 2014 to reflect lower harvest volumes, expectations for slower log price growth, and the anticipated composition of real estate transactions in the second half of the year.

The company now expect earnings of $1.05 to $1.25 per share, against prior outlook of $1.30 to $1.50 per share. Analysts currently expect earnings of $1.39 per share for 2014.

PCL closed Monday's trading at $43.91, up $0.14 or 0.32%, on the NYSE. The stock however dropped $1.21 or 2.76% in after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT